Safety of zonisamide therapy: prospective follow-up survey  by Ohtahara, Shunsuke & Yamatogi, Yasuko
Seizure (2004) 13S, S50—S55
Safety of zonisamide therapy: prospective
follow-up survey
Shunsuke Ohtahara*, Yasuko Yamatogi
Department of Child Neurology, Okayama University Medical School, Shikata-cho 2-5-1, Okayama
700-8588, Japan
KEYWORDS
Zonisamide;
Epilepsy;
Japan;
Adverse effects;
Safety
Summary Zonisamide safety was evaluated based on a postmarketing surveillance
study of patients treated for 1–3 years. Nine hundred twenty-eight children and 584
adults (ages 1 month to 79 years), including 372 newly-diagnosed patients, received
zonisamide for partial and generalized epilepsies. Of the intractable patients, 1008
received zonisamide in combination with other antiepileptic drugs (AED), and 52 suc-
cessfully transitioned to zonisamide monotherapy. A total of 1089 adverse events
occurred in 476 (31.5%) of 1512 patients. Incidence of adverse effects was signif-
icantly lower among patients receiving zonisamide monotherapy than in those re-
ceiving polytherapy: 21% (18.9% of children, 29.4% of adults) versus 35.6% (30.4% of
children, 41.7% of adults), respectively. The total incidence of adverse effects was
lower for children (26.2%) than for adults (39.9%). Most common adverse events in-
cluded mental/psychiatric symptoms (19.4%), gastrointestinal symptoms (8.7%), and
neurological symptoms (5.8%). Effects that seemed unique to zonisamide were im-
pairment of mental function, motivation or volition, and hypohidrosis. Urinary calculi
were detected in only two patients (0.13%). Teratogenicity was evaluated in six pa-
tients. Two patients on zonisamide monotherapy and three on polytherapy delivered
normal children. One of four patients on polytherapy conceived a fetus with a skull
defect with cerebral and cerebellar dysgenesis.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Zonisamide has been proven to be a useful
antiepileptic drug (AED) with a broad therapeutic
spectrum.1–5 It has shown efﬁcacy for intractable
epilepsies including frontal lobe epilepsy, West and
Lennox–Gastaut syndromes, and severe myoclonic
epilepsy in infancy.6,7 The safety of zonisamide,
including adverse effects and teratogenicity, was
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examined in a postmarketing prospective follow-up
survey of Japanese patients treated for 1–3 years
with zonisamide, either as monotherapy or as a
component of polytherapy.
Methods
Twenty-three groups of clinical epileptologists and
two independent clinicians registered 1793 patients
having active partial and generalized epilepsy who
had had no previous zonisamide therapy. Data on
clinical seizure symptoms and frequency, general
conditions, electroencephalogram (EEG), and lab-
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oratory test results were collected prior to zon-
isamide treatment. Physicians performed regular
follow-up examinations for up to 3 years.
Of registered patients, 1512 were included
in the safety analysis: 928 children who ranged
from 2 months to 15 years of age, and 584 adult
epilepsy patients ages 16–79 years. Three hundred
seventy-two patients were newly treated with zon-
isamide alone; 52 others were successfully switched
to monotherapy; and 1088 received polytherapy
that included zonisamide. Of the total, 1044 pa-
tients had partial epilepsy, 458 had generalized
epilepsy, and 10 had other epilepsies or were un-
classiﬁable. Among these 1512 patients, 885 were
treated with zonisamide for at least 1 year and 493
received zonisamide for 2 or more years.
Adverse events were based on clinician reports
and included events with and without causal rela-
tionships to zonisamide.
Results
Incidence of adverse effects
One thousand eighty-nine adverse events were re-
ported by 478 (31.6%) of 1512 patients. Children
had a signiﬁcantly lower incidence rate of adverse
effects than adults, 24.3% (244/928 cases) versus
40.1% (234/584 cases) (P < 0.001), respectively
(Fig. 1). The rate of adverse effects was signiﬁ-
cantly lower in patients treated with zonisamide
monotherapy versus polytherapy: 21.0% (89/424
cases) versus 35.8% (389/1088 cases) (P < 0.001),
respectively (Table 1). The incidence was also sig-
niﬁcantly lower in children than adults in both
monotherapy and polytherapy: 18.9% versus 29.4%
Figure 1 Incidence of adverse effects: children vs. adults.
(P < 0.05), and 30.6% versus 41.9% (P < 0.001),
respectively (Fig. 1).
Classiﬁcation of adverse effects
General trends
The most frequently observed adverse effects oc-
curred in the central nervous system (CNS), with
mental/psychiatric symptoms reported for 293 pa-
tients (19.4%). Although mental symptoms were
distributed proportionately among children and
adults, the rate was higher in the polytherapy group
(21.5%; 20.7% of children and 22.6% of adults) than
in the monotherapy group (13.7%; 13.6% of children
and 14.1% of adults) (P < 0.001).
Ninety-ﬁve adverse events of general condition
were reported in 80 patients (5.3%). These in-
cluded weight loss in 42 patients (2.8%), malaise
in 27 (1.8%), weakness in 14 (0.9%), and fever in 9
(0.6%). Adverse effects in the urinary, circulatory,
and respiratory systems were rarely observed.
Hepatic adverse effects–—85 events in 36
patients–—involved liver enzyme activities, includ-
ing increased aspartate aminotransferase, alanine
aminotransferase, or -glutamyl transpeptidase.
Mental and psychiatric symptoms
Themain symptomwas sleepiness, which was noted
in 246 patients (16.3%). Although it was higher in
the polytherapy group (18.0%) (P < 0.01), the rate
was high in the monotherapy group as well (11.8%).
Speciﬁc symptoms included enervation in 43
patients (2.8%); loss of spontaneity in 41 (2.7%);
decreased mental activity in 36 (2.4%); irritable or
excitable behavior disorders in 45 (3.0%); and psy-
chiatric symptoms such as depression in 8 (0.5%);
hallucination or delusion in 12 (0.8%); and anxiety or
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Table 1 Adverse effects of zonisamide.
Children or Adults AE (+) n (%) AE (−) n (%) Total P value
Monotherapy Children 64 (18.9) 275 (81.1) 339 P = 0.0330
Adults 25 (29.4) 60 (70.6) 85
Polytherapy Children 180 (30.6) 409 (69.4) 589 P = 0.0001
Adults 209 (41.9) 290 (58.1) 499
Combination Children 244 (26.3) 684 (73.7) 928 P = 0.0001
Adults 234 (40.1) 350 (59.9) 584
hypochondria in 14 (0.9%). These adverse effects
were not always dose-related, but often appeared
within therapeutic serum levels. Overall, the num-
ber of patients reporting psychiatric symptoms was
small.
Neurological adverse effects
Neurological symptoms were observed in 88 pa-
tients (5.8%). These included ataxia or disequilib-
rium in 50 patients (3.3%), vertigo or dizziness in
16 (1.1%), diplopia in 17 (1.1%), and dyslalia in 9
(0.6%). These effects were rarely observed in the
patients receiving zonisamide monotherapy, but
occurred signiﬁcantly more often in those with
polytherapy (P < 0.001). The strong inﬂuence of
combined AEDs was suggested as the reason for
these adverse effects.
Tremor/involuntary movement (11 patients,
0.7%) and headache (29 patients, 1.9%) were ob-
served in both mono- and polytherapy groups, indi-
cating a possible causal relation to the basic illness
or epilepsy itself. The aggravation of seizures or in-
duction of new seizures or microseizures8 occurred
in three patients (0.2%).
Dermatologic adverse effects
Skin rash was observed in 21 patients (1.4%) and
itching in 8 (0.5%). Hypohidrosis was observed in
14 patients (0.9%), predominantly children receiv-
ing polytherapy, and often accompanied by fever,
usually in summer.
Gastrointestinal symptoms
Gastrointestinal symptoms noted in 132 patients
(8.7%) included anorexia in 99 (6.5%), nausea in
33 (2.2%), vomiting in 20 (1.3%), and abdominal
pain in 9 (0.6%). Anorexia was observed signiﬁcantly
more often in patients treated with polytherapy, 87
(8.0%), (P < 0.001), but was also noted in 12 pa-
tients (2.8%) receiving zonisamide monotherapy.
Urologic symptoms
Urologic adverse effects occurring in 14 patients
(0.9%) included four patients (0.3%) each experi-
encing urinary incontinence and enuresis, and three
(0.2%) with hematuria. Urolithiasis was suspected in
two adult male patients (0.1%), one of whom had a
past history of urinary tract calculi 15 years earlier.
Teratogenicity
Six women in the study were treated with zon-
isamide during pregnancy. Two patients on mono-
therapy delivered healthy children. Out of four pa-
tients on polytherapy, a fetal malformation of skull
defect with cerebral and cerebellar hypogenesis
was reported in one patient under combination
with phenytoin. The other three patients delivered
normal children.
Severity of adverse events
According to a subjective severity evaluation by
each epileptologist, the 1089 adverse events oc-
curring in 478 of 1512 patients were classiﬁed as
follows: 602 mild events (55.3%), 416 of moder-
ate severity (38.2%), and 58 severe events (5.3%).
Severity was not reported in 13 events.
Severe adverse events included seizure aggra-
vation (including induced microseizures), hypo-
hidrosis, anorexia and weight loss, and mental
symptoms, such as decreased spontaneity or de-
pressed mental activity, psychotic state, and irri-
tability.
Seizure aggravation and idiosyncratic adverse
effects, such as skin rash, fever, and agranulocy-
tosis, appeared relatively early and in low doses
of zonisamide. Mental symptoms, anorexia, and
weight loss, however, varied greatly in time of ap-
pearance and the dosage in which they occurred.
Zonisamide was discontinued in 55.2% of the
patients with severe adverse events.
Adverse effects observed in long-term use
Of the 1512 total patients, 864 were treated with
zonisamide for more than 1 year. Eight hundred
eighty-one adverse events were experienced by
433 of 1512 study participants (28.6%) within the
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ﬁrst year of zonisamide treatment; 208 events
occurred in 120 of 864 patients (13.9%) in the sec-
ond year or later. Late appearing adverse effects
included one case each of bowel incontinence, pal-
pitation, micturition disorder, muscle weakness,
increased lactate dehydrogenase, decreased IgA,
and increased blood urea nitrogen. Severe adverse
effects observed in the second year or later in-
cluded two cases of psychotic state, and one case
each of auditory hallucination, anorexia, weight
loss, nausea, and vomiting.
Laboratory data showed that -glutamyl transpep-
tidase abnormalities were signiﬁcantly higher in
the second year than the ﬁrst year: 17 out of 588
cases (2.89%) versus 14 out of 1011 cases (1.38%)
(P = 0.05), respectively.
Factors related to incidence of
adverse effects
Sex
Sex difference had no inﬂuence on the incidence of
adverse effects.
Age
One factor clearly related to the appearance of ad-
verse effects is age, with adverse effects occurring
less frequently among children than among adults.
Speciﬁcally, adverse effects were experienced by
24.1% (164/680) of children younger than 12 years
of age, without signiﬁcant difference among sub-
divided age groups, followed by a gradual increase
to 50 years of age; 31.8% (79/248) of patients ages
12–15; 38.4% (53/138) in ages 16–19; 41.2% (77/187)
in ages 20–29; 42.1% (53/126) in ages 30–39; and
43.9% (29/66) in ages 40–49. However, this trend
started to reverse among patients 50 years and
older; 33.3% (16/48) of patients ages 50–59 expe-
rienced adverse effects; 26.3% (5/19) of patients
ages 60 and older; and 16.7% (1/6) of those 65 and
older.
A similar age-related tendency was observed in
monotherapy and polytherapy groups; however,
there was considerable variation in the incidence
of adverse events among age categories in the
monotherapy group, presumably due to the small
number of patients in each category.
Classiﬁcation of epilepsy
The type of epilepsy had no apparent effect on the
incidence of adverse effects. Among patients on
monotherapy, no difference was seen between par-
tial epilepsy, 72/336 patients (21.4%), and gener-
alized epilepsies, 17/88 (19.3%). This was true in
the polytherapy group as well, where no difference
was seen between partial epilepsy cases, 259/708
(36.6%), and generalized epilepsy cases, 125/370
(33.8%).
Neurological complications
Neurological abnormalities, such as mental retar-
dation, motor disturbances, or behavior disorders
seemed to contribute to a signiﬁcantly higher inci-
dence of adverse effects; 340/931 (36.5%) versus
213/785 (27.1%) in total patients (P < 0.001).
When subcategorized into monotherapy versus
polytherapy: 27/110 (24.5%) versus 64/332 (19.3%)
occurred in monotherapy, and 313/821 (38.1%) ver-
sus 149/453 (32.9%) in polytherapy. The incidence
was not statistically signiﬁcant.
Zonisamide dosage
Rates of adverse effects were inversely related
to doses of zonisamide. Children taking 2mg/kg
per day or less, and adults taking 100mg per
day or less of zonisamide showed the highest
adverse events incidence. This tendency corre-
sponds to the ﬁnding that 34.2% of adverse events
appeared within the ﬁrst month of zonisamide
initiation.
Number of combined antiepileptic drugs
When compared to 21.0% (89/424) of adverse
events experienced in monotherapy, a signiﬁcant
increase in adverse events was noted when zon-
isamide was combined with up to three additional
AEDs; an even greater increase occurred in com-
binations of four to ﬁve AEDs (P < 0.001). There
was a 32.6% (103/316) increase with one additional
AED; 36.6% (150/410) with two other AEDs; 33.3%
(80/240) with three other AEDs; and 43.8% (53/121)
with an additional four to ﬁve AEDs (Fig. 2).
Figure 2 Incidence of adverse effects: monotherapy vs.
polytherapy.
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Discussion
The rate of adverse events (31.5%) found in this
study is lower than the 51.3% (517/1008 cases) ob-
served in the clinical developmental studies,1 per-
haps because of the increased proportion of pa-
tients receiving zonisamide monotherapy (28.0%)
experienced a lower rate of adverse effects than
those receiving polytherapy.
Among the common adverse effects involving the
central nervous system, neurological effects such
as ataxia, vertigo, and double vision were probably
toxic effects elicited in a dose-related manner, as
was the case with other AEDs.
On the other hand, troublesome adverse effects
involving the higher brain function, such as im-
paired mental and cognitive activities,9 decreased
motivation or volition, psychiatric symptoms,10–12
and behavior disorders,13 may have serious effects
on patients’ academic or social lives. Although
these are usually aggravated dose-dependently,9
they may appear in relatively low doses10–13 and
often result in the discontinuation of zonisamide.
These effects relating to the higher brain func-
tion were suggested to be speciﬁc for zonisamide,
considering a relatively high detection rate in
monotherapy and improvement by discontinua-
tion of zonisamide. Some of this aspect may be
evaluated by neurophysiological methods such as
event-related potentials.7
Because 110 of 246 patients (44.7%) with sleepi-
ness reported this complaint during the ﬁrst month
of administration, this adverse effect may be the
result of a high initial dose and subsequent rapid
dose increase. Administering a low initial dose fol-
lowed by a gradual dose increase may minimize this
effect.
Seizure aggravation or induction of new seizures,
such as induced microseizures,7,8 was reported in
three cases (0.2%). Because all of these occurred
under polytherapy, seizure-inducing effects of zon-
isamide, like those noted with benzodiazepines,
warrant further study.
Hypohidrosis is a peculiar adverse event for
zonisamide. Its incidence was only 0.9% in this
survey, partly because the study included 584
adults (38.6%). It may not, however, be a rare
adverse effect in infancy and childhood, as hypo-
hidrosis was observed in 12 (17.1%) of 70 children
with epilepsy by Okumura et al.14 and 38 (24.8%)
of 153 cases by Hosoda et al.15 The decreased
sweating response to acetylcholine loading sug-
gests the functional suppression of sweat glands
by zonisamide as its mechanism.14 Accordingly,
a probable dose-dependent decrease in sweating
should be considered as a cause of fever in infants
and severely handicapped children on zonisamide
(mainly polytherapy), particularly in summer time.
Urolithiasis had been a problem in trials in the
United States and Europe.1–5 In this series, it was
suspected in two adult male cases (0.1%), however,
the incidence of two men out of 280 male subjects
(0.71%) was not higher than the 1.3% rate in the
general Japanesemale population.16 Notwithstand-
ing, Kubota et al.17 suggested an increased risk of
urolithiasis in patients who are bedridden and/or
receiving zonisamide polytherapy.
Among the gastrointestinal symptoms, loss of
appetite is one of the main characteristics,1,4
sometimes having serious adverse effects. This
may occur with relatively low doses of zonisamide,
and often worsens in relationship to dose, leading
to considerable weight loss that may necessitate a
decrease in dose or discontinuation of zonisamide.
Its long serum half-life of over 50 h may enable QD
(once-a-day) administration after dinner to mini-
mize anorexia.
Concerning teratogenicity, of all 25 known births
or pregnancies during the zonisamide pre- and
postmarketing periods, two had malformation
(8.0%), including one fetus with anencephaly. The
other child was born with an atrial septal defect
to a women treated with combination therapy that
included phenytoin and valproate.18
The limited number of pregnancies during zon-
isamide treatment18 and the extent of teratogenic-
ity suggested by animal trials,19,20 indicate the need
for further precise clinical investigations on ter-
atogenicity. Administration of new drugs to women
of childbearing age should be carefully considered,
and used only when remarkable efﬁcacy is con-
ﬁrmed and there is no other alternative treatment.
Factors relating to the appearance of adverse
effects include the age factor—that is, a lower
incidence in those younger than 12 years, and
higher in those of 20–50 years. Differences in phar-
macokinetics, including drug metabolism and the
higher proportion of polytherapy in adult patients
(499/584, 85.4%) than children (589/928, 63.5%),
may provide an explanation.
Classiﬁcation of epilepsy probably has no direct
relation to adverse effects. Intractable epilepsies,
such as Lennox-Gastaut syndrome and temporal
lobe epilepsy, however, may indirectly relate to
the high incidence of adverse effects, reﬂecting
the need for polytherapy or high-dose treatment in
such patients. Likewise, this may account for the
association of neurological abnormalities with the
high proportion of intractable epilepsies.
It appears this drug’s incidence of adverse events
inversely relates to a lower administration dose.
This would indicate the need for a careful initia-
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tion of zonisamide treatment. Moreover, adverse ef-
fects often appear within the ﬁrst month after zon-
isamide induction. Starting with as low a dose as
possible, and gradually increasing the dose to con-
ﬁrm tolerance, may minimize adverse effects.
Conclusion
Zonisamide is a potent AED with a broad spectrum
of effectiveness for both partial and generalized
epilepsies. However, speciﬁc adverse effects such
as pseudodementia (impaired mental activities),
decreased volition, anorexia, and hypohidrosis
warrant caution and may restrict its clinical appli-
cation.
To raise availability and tolerability, and re-
duce associated adverse effects of zonisamide: (1)
monotherapy (or polytherapy with as few additional
AED as possible) is recommended. In addition, (2)
the once-a-day administration of zonisamide (up
to the 2–3mg/kg per day) after the evening meal;
(3) initial doses less than 1mg/kg per day; and (4)
gradual dose increase up to 5mg/kg per day and
then 10mg/kg per day in small increments over
an extended time interval, may help alleviate the
drowsiness, anorexia, and weight loss associated
with zonisamide therapy.
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